Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Ovarian Neoplasms

  Free Subscription


02.04.2018

4 BMC Cancer
1 Cancer Chemother Pharmacol
2 Cancer Lett
8 Gynecol Oncol
1 J Natl Cancer Inst
2 PLoS One


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    BMC Cancer

  1. WANG S, Wei H, Zhang S
    Dickkopf-4 is frequently overexpressed in epithelial ovarian carcinoma and promotes tumor invasion.
    BMC Cancer. 2017;17:455.
    PubMed     Text format     Abstract available

  2. GEORGE A, McLachlan J, Tunariu N, Della Pepa C, et al
    The role of hormonal therapy in patients with relapsed high-grade ovarian carcinoma: a retrospective series of tamoxifen and letrozole.
    BMC Cancer. 2017;17:456.
    PubMed     Text format     Abstract available

  3. ZHAO D, Wang X, Zhang W
    GDF15 predict platinum response during first-line chemotherapy and can act as a complementary diagnostic serum biomarker with CA125 in epithelial ovarian cancer.
    BMC Cancer. 2018;18:328.
    PubMed     Text format     Abstract available

  4. LE PAGE C, Rahimi K, Kobel M, Tonin PN, et al
    Characteristics and outcome of the COEUR Canadian validation cohort for ovarian cancer biomarkers.
    BMC Cancer. 2018;18:347.
    PubMed     Text format     Abstract available


    Cancer Chemother Pharmacol

  5. XIAO F, Li Y, Wan Y, Xue M, et al
    MircroRNA-139 sensitizes ovarian cancer cell to cisplatin-based chemotherapy through regulation of ATP7A/B.
    Cancer Chemother Pharmacol. 2018 Mar 28. pii: 10.1007/s00280-018-3548.
    PubMed     Text format     Abstract available


    Cancer Lett

  6. VAN HEETVELDE M, Van Bockstal M, Poppe B, Lambein K, et al
    Accurate detection and quantification of epigenetic and genetic second hits in BRCA1 and BRCA2-associated hereditary breast and ovarian cancer reveals multiple co-acting second hits.
    Cancer Lett. 2018 Mar 23. pii: S0304-3835(18)30223.
    PubMed     Text format     Abstract available

  7. VIRANI NA, Thavathiru E, McKernan P, Moore K, et al
    Anti-CD73 and Anti-OX40 immunotherapy coupled with a novel biocompatible enzyme prodrug system for the treatment of recurrent, metastatic ovarian cancer.
    Cancer Lett. 2018 Mar 21. pii: S0304-3835(18)30224.
    PubMed     Text format     Abstract available


    Gynecol Oncol

  8. WILSON AJ, Stubbs M, Liu P, Ruggeri B, et al
    The BET inhibitor INCB054329 reduces homologous recombination efficiency and augments PARP inhibitor activity in ovarian cancer.
    Gynecol Oncol. 2018 Mar 20. pii: S0090-8258(18)30229.
    PubMed     Text format     Abstract available

  9. MCDONALD JF
    Back to the future - The integration of big data with machine learning is re-establishing the importance of predictive correlations in ovarian cancer diagnostics and therapeutics.
    Gynecol Oncol. 2018 Mar 20. pii: S0090-8258(18)30233.
    PubMed     Text format    

  10. LONG J, Zhu JY, Liu YB, Fu K, et al
    Helicase POLQ-like (HELQ) as a novel indicator of platinum-based chemoresistance for epithelial ovarian cancer.
    Gynecol Oncol. 2018 Mar 20. pii: S0090-8258(18)30176.
    PubMed     Text format     Abstract available

  11. MATSUOKA A, Tate S, Nishikimi K, Shozu M, et al
    Efficacy of soft coagulation in retroperitoneal lymphadenectomy for ovarian cancer.
    Gynecol Oncol. 2018 Mar 21. pii: S0090-8258(18)30231.
    PubMed     Text format    

  12. COWAN RA, Tseng J, Ali N, Dearie H, et al
    Exploring the impact of income and race on survival for women with advanced ovarian cancer undergoing primary debulking surgery at a high-volume center.
    Gynecol Oncol. 2018;149:43-48.
    PubMed     Text format     Abstract available

  13. DILLEY S, Erickson BK, Phillips CE, Kennemer CR, et al
    Do differences in medical comorbidities and treatment impact racial disparities in epithelial ovarian cancer?
    Gynecol Oncol. 2018;149:49-52.
    PubMed     Text format     Abstract available

  14. MANRRIQUEZ E, Chapman JS, Mak J, Blanco AM, et al
    Disparities in genetics assessment for women with ovarian cancer: Can we do better?
    Gynecol Oncol. 2018;149:84-88.
    PubMed     Text format     Abstract available

  15. BONHOF CS, Mols F, Vos MC, Pijnenborg JMA, et al
    Course of chemotherapy-induced peripheral neuropathy and its impact on health-related quality of life among ovarian cancer patients: A longitudinal study.
    Gynecol Oncol. 2018 Mar 28. pii: S0090-8258(18)30232.
    PubMed     Text format     Abstract available


    J Natl Cancer Inst

  16. HILLMAN RT, Chisholm GB, Lu KH, Futreal PA, et al
    Genomic Rearrangement Signatures and Clinical Outcomes in High-Grade Serous Ovarian Cancer.
    J Natl Cancer Inst. 2018;110.
    PubMed     Text format     Abstract available


    PLoS One

  17. CHUDECKA-GLAZ A, Cymbaluk-Ploska A, Wezowska M, Menkiszak J, et al
    Could HE4 level measurements during first-line chemotherapy predict response to treatment among ovarian cancer patients?
    PLoS One. 2018;13:e0194270.
    PubMed     Text format     Abstract available

  18. CHANG LC, Huang CF, Lai MS, Shen LJ, et al
    Prognostic factors in epithelial ovarian cancer: A population-based study.
    PLoS One. 2018;13:e0194993.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Ovarian Neoplasms is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: